Preclinical studies demonstrated that sacituzumab govitecan can selectively bind to Trop2+ tumor cells, causing double-stranded DNA breaks and tumor cell death by topoisomerase I and bystander effect. This evidence concerns the gene TACSTD2 and neoplasm.